Viewing Study NCT06253494

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:40 AM
Ignite Modification Date: 2026-02-09 @ 1:50 PM
Study NCT ID: NCT06253494
Status: RECRUITING
Last Update Posted: 2025-12-01
First Post: 2024-02-09
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Endometrial Cancer View
None Cancer of Endometrium View
None Carcinoma of Endometrium View
None Endometrial Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Cancer Vaccine View
None Combination of anti-cancer drugs View
None Immunotherapy View
None HER2 Positive Cancer View